trialsitenews's podcast

We discuss "Smart" Natural Killer Cells for Cancer Treatment, Sonny Hsiao of Acepodia. A clinical trial targeting HER2-expressing solid tumors with “smart” NK cells.

Sonny Hsiao is the founder and CEO of Acepodia. Founded in 2016 the company seeks to develop new therapies in immune-oncology and cell therapy medicine. Put another way Acepodia is a novel technology platform that serves to arm immune cells with antibodies to cure cancer.

Company Website: www.acepodia.com LinkedIn: https://www.linkedin.com/in/sonny-hsiao-83199956/

An Interview with Dr. Ian Smith, Founder, Director and Chief Medical Officer of Panthera Biopartners and CEO of Panthera Biopartners Stuart Young discussing the Lessons from Covid-19 and the differing strategies for recruiting and retaining patients in oncology and chronic diseases including CNS, Rheumatoid arthritis, Nash and cardiovascular.

About Panthera: An independent site management organization run by a world-class team of experts, finds patients and runs clinical trials on behalf of CROs and pharma companies across multiple therapeutic areas. https://www.panthera-bio.com/

About Dr. Ian Smith: Dr. Ian founded Synexus, the world’s first independent clinical trials organization, whilst practicing as a GP. He went on to build the Synexus model into the foremost SMO with sites across the world.

Today Ian is a non-executive director of several healthcare companies. Ian was awarded an MBE for services to health research.

About CEO Stuart Young Stuart previously managed the UK division of Synexus overseeing nine dedicated research sites. Stuart is particularly focused on the use of technology to reduce costs in clinical trials, provide a first rate patient experience and ensure that Panthera is at the cutting edge of clinical research.

Stuart, holds a degree in Mechanical Engineering from University of Strathclyde in Glasgow, has had extensive experience in data management and the introduction of new technologies into organizations.

Claudia Christian of FHI Clinical discusses Covid-19 impact on Clinical Trials. The challenge of patient recruitment in Clinical Trials

Claudia Christian is the Senior Vice President, Clinical Operations of FHI Clinical. FHI Clinical has, among other things provided clinical operations services for ACTT-1 trial of remdesivir for treatment of COVID-19. Claudia Christian has held positions in pharmaceutical, biotech and CROs across multiple indications. Since 2014, she has devoted her expertise full-time to infectious disease research, including managing multiple study protocols and developing sites in support of outbreak responses.

https://www.fhiclinical.com/the-elusive-covid-19-patient-subject-recruitment-remains-challenging-despite-increasing-case-numbers/

We sit down and talk to Dr. Abribat about Amolyt Pharma, which is developing therapeutic peptides to treat rare endocrine and metabolic diseases. The company recently announced that it has dosed the first patient in a Phase 1 clinical trial evaluating its experimental therapeutic peptide, AZP-3601, for a life-altering rare disease called hypoparathyroidism. This is Amolyt’s first clinical trial as a company. The trial, being conducted at sites in Europe, will test whether AZP-3601 will benefit patients with hypoparathyroidism by restoring lasting levels of calcium in their blood. Thierry Abribat, PhD can discuss why therapeutic peptides may provide better treatment options for patients with rare endocrine and metabolic diseases, the unmet need in hypoparathyroidism, AZP-360 and the ongoing trial

Dr. David Horn Solomon, CEO of Pharnext discusses PXT3003 which is currently focused on the treatment of Charcot Marie-Tooth (CMT) disease Type 1A. Charcot-Marie-Tooth is a degenerative nerve disease that usually appears in adolescence or early adulthood. CMT affects the Peripheral Nervous System. It is a progressive nerve disease. Nerves weaken over time, causing progressive disability starting in the toes and fingers and working toward the center of the body.

You can visit Pharnext by clicking on this link: https://pharnext.com/

About: Dr. Solomon is a leader in the life sciences industry with a 30+ year track record. Prior to joining Pharnext, David served as the CEO of Silence Therapeutics (NASDAQ:SLN), Akari Therapeutics (NASDAQ:AKRI), Bionor Pharma (OSLO:BIONOR), and Zealand Pharma (NASDAQ:ZEAL) guiding Zealand through approval of Adlixin for Type II Diabetes. He was Managing Partner at Sund Capital in Denmark and also headed healthcare investments at Carrot Capital Healthcare Ventures in New York City. A former Board member of TxCell (acquired by Sangamo Therapeutics), Onxeo, and Promosome, David is currently Chairman of the Board for Advicenne Pharma (PARIS: ADV) and Rexgenero in London. David was earlier a Professor of Pharmacology and Neurology at Columbia University’s College of Physicians and Surgeons in New York City.

Dr. Lenze discusses a clinical trial conducted by Washington University School of Medicine in St. Louis which evidences the potential that fluvoxamine, an antidepressant, may prevent COVID-19 infections from worsening. This trial is based on recent research that originates from the University of Virginia School of Medicine.

Website: https://stopcovidtrial.wustl.edu/

Phone: 314-747-1137

Email: [email protected]

Dr. Ragen discusses X4 Pharmaceuticals, which is currently developing therapies for rare genetic diseases that result from dysfunction of the immune system and is currently undergoing a global Phase 3 trial for WHIM Syndrome and two Phase 1b trials for Waldenstrom macroglobulinemia (WM), a type of rare lymphoma, and severe congenital neutropenia (SCN).

We sit down with Dr. CJ Barnum, Director of Neuroscience at Inmune Bio, Inc. to talk about the recently announced grant from the NIH for $2.9 million to test a new hypothesis that #neuroinflammation plays a major role in treatment resistant depression (TRD).

This money will support a first-of-its-kind phase 2 study that will be conducted at two sites in the U.S. – Emory University School of Medicine in Atlanta and University of Alabama in Birmingham. Patient enrollment will be based on levels of inflammatory biomarkers and anhedonia, rather than being an all-comers study which is the standard in today’s psychology trials.

We also discuss INmune Bio Inc.'s developing novel therapies targeting distinct parts of the patient's immune system to fight disease. This includes drug candidates to treat #cancer, and #Alzheimers disease.

To find out more about Inmune Bio Inc. you can check out there website: https://inmunebio.com/

Hartmut Ehrlich and Philippe Pouletty discuss Abivax Pipeline of Clinical Programs involving Covid-19, Ulcerative Colitis, Crohn's Disease and more. https://www.abivax.com/pipeline/

- #COVID-19 https://www.abivax.com/pipeline/abx464-for-covid-19/ Ongoing Phase 2b/3 trial with ABX464 in Covid-19 (miR-AGE trial), the unique properties of the lead candidate (antiviral, anti-inflammatory, tissue repair) to treat elderly and high-risk Covid-19 patients, the rial is ongoing in Europe and Brazil (Mexico, Peru and Chile to follow shortly)

-#Cancer https://www.abivax.com/pipeline/abx196/ ABX196 has been developed as a synthetic agonist of iNKT cells from a proprietary platform technology that identifies agonists of these types of cells that demonstrate immune enhancing effects in cancer models. Preclinical data showed that ABX196 enhanced anti-tumoral activity when used alone and in combination with anti-PD1 antibodies or doxorubicin.

- Ulcerative Colitis https://www.abivax.com/pipeline/abx464-ibd-uc/ ABX464 in Inflammatory Bowel Diseases (Abivax development priority), excellent two-year efficacy and safety data for ABX464 ulcerative colitis Phase 2a maintenance study and ongoing ulcerative colitis Phase 2b trial in 15 countries, the US and Canada

- Crohn’s disease https://www.abivax.com/pipeline/abx464-for-crohns-disease/ Planned pivotal Phase 2b/3 trial with ABX464 in Crohn’s disease (FPI Q1 2021) and ngoing clinical trial with ABX464 in rheumatoid arthritis in 5 European countries

- HC Ongoing clinical trial with second molecule, ABX196, in patients with hepatocellular carcinoma in the US

Dr. Negin Hajizadeh discussing Feinstein Institutes researchers finding an effective COVID-19 ‘cytokine storm’ treatment and more. Dr. Hajizadeh is an ICU pulmonologist and was a part of Northwell Health's, NY largest health system, at the height of the surge. She has experienced and delivered care first hand. She is also a researcher with the Feinstein Institutes.

#Recovery trial #Covid-19